Imetelstat Sodium not checked

Geron Corporation · GRN163L

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
4 active
7 in total · 2 in the EU
Targets
 

What this is

How it works
Oligonucleotide Telomerase Inhibitor FDA class
How it’s given
“imetelstat will be given intravenously at 3.55 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.”In the company’s words, NCT07939451 on ClinicalTrials.gov
Tested for
Myelofibrosis (2 trials), MDS (Myelodysplastic Syndrome), MDS, Myelodysplastic Syndromes
Main trialPhase 4
“This study is testing two doses of imetelstat in adults with lower-risk myelodysplastic syndrome, or MDS. The study will include about 100 adults in several countries. To be eligible, participants must have lower-risk MDS, need frequent red blood cell transfusions, and have already tried-or cannot use-other treatments for anemia. Participants will be randomly placed into one of two groups. One group will receive the usual dose of imetelstat, 7.1 mg/kg of body weight. The other group will receive a lower dose, 3.55 mg/kg. Both doses are given through a vein during a roughly two-hour clinic…”In the company’s words, NCT07939451 on ClinicalTrials.gov
Other names
GRN163L · Imetelstat

Other drugs for Myelofibrosis

All 37 drugs for Myelofibrosis

Coming up3

Changes1

Last 90 days

Trials7

TrialPhaseCompletesWhat it tests
Phase 4Not yet recruiting Jul 2030 A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
Phase 3Active, not recruiting 30 Jun 2028 A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Phase 2/3Active, not recruiting 13 Oct 2023 Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1Active, not recruiting Feb 2027 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Phase 2Completed Nov 2014 Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Phase 2Completed 26 Apr 2018 Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Phase 2Completed 24 May 2018 Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Imetelstat Sodium

Following is part of Solo: you see every change to Imetelstat Sodium the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in